Literature DB >> 8077726

C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.

F L Njoo1, C E Hack, J Oosting, L Luyendijk, J S Stilma, A Kijlstra.   

Abstract

Ivermectin treatment of onchocerciasis can induce adverse reactions. Mechanisms underlying these reactions are poorly understood but may include activation of neutrophils. This study investigated the acute-phase response in onchocerciasis patients during 2 days after ivermectin treatment. The acute-phase protein C-reactive protein (CRP) and cytokines that mediate the acute-phase response (tumor necrosis factor-alpha [TNF alpha] and interleukin-6 [IL-6]) were measured in 144 skin snip-positive onchocerciasis patients and 12 skin snip-negative controls who received one dose of ivermectin (150 micrograms/kg). No elevated TNF alpha levels were found, but IL-6 and CRP were elevated in 25.7% and 50.7% of the patients, respectively, after ivermectin treatment. Most patients (89.2%) with raised IL-6 also had raised CRP. Such increases were not observed in controls and in patients were correlated with adverse reactions and microfilarial densities. These findings suggest a possible role of the acute-phase response in microfilarial destruction following ivermectin treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077726     DOI: 10.1093/infdis/170.3.663

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Effects of parasitic helminths and ivermectin treatment on clinical parameters in the European wild boar (Sus scrofa).

Authors:  Jorge R López-Olvera; Ursula Höfle; Joaquín Vicente; Isabel G Fernández-de-Mera; Christian Gortázar
Journal:  Parasitol Res       Date:  2006-01-26       Impact factor: 2.289

Review 2.  How do the macrocyclic lactones kill filarial nematode larvae?

Authors:  Adrian J Wolstenholme; Mary J Maclean; Ruby Coates; Ciaran J McCoy; Barbara J Reaves
Journal:  Invert Neurosci       Date:  2016-06-09

3.  Protective responses against skin-dwelling microfilariae of Onchocerca lienalis in severe combined immunodeficient mice.

Authors:  S G Folkard; M J Taylor; G A Butcher; A E Bianco
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Elevated serum angiotensin-converting enzyme activity in onchocerciasis.

Authors:  M J Ronday; A Van der Lelij; M Wienesen; A Rothova; J S Stilma; A Kijlstra
Journal:  Lung       Date:  1996       Impact factor: 2.584

Review 5.  The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?

Authors:  Helen Onyeaka; Phemelo Tamasiga; Joy O Agbara; Oreneile Anikie Mokgwathi; Olivier Uwishema
Journal:  Clin Epidemiol Glob Health       Date:  2022-06-08

6.  Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.

Authors:  Kwablah Awadzi
Journal:  Filaria J       Date:  2003-10-24

Review 7.  Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.

Authors:  Harpinder Kaur; Nishant Shekhar; Saurabh Sharma; Phulen Sarma; Ajay Prakash; Bikash Medhi
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

Review 8.  Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.

Authors:  Zena Wehbe; Maya Wehbe; Rabah Iratni; Gianfranco Pintus; Hassan Zaraket; Hadi M Yassine; Ali H Eid
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.